Open AccessSequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer
Author(s) -
Yago Nieto,
José Manuel Aramendía,
Jaime Espinós,
Susana De La Cruz,
Óscar Fernández-Hidalgo,
Marta Santisteban,
L. Arbea,
Javier Aristu,
Rafael MartínezMonge,
Marta Moreno,
Luis Pina,
Josu Sola,
G Zornoza,
Fernando Martínez Regueira
Publication year - 2009
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-009-1049-y
Subject(s) - capecitabine , medicine , docetaxel , epirubicin , breast cancer , metastatic breast cancer , cyclophosphamide , oncology , chemotherapy , gastroenterology , urology , cancer , surgery , colorectal cancer
Capecitabine is effective against metastatic breast cancer (MBC). We hypothesized that sequential treatment with dose-dense epirubicin/cyclophosphamide (EC) and docetaxel/capecitabine would be active and tolerable in the adjuvant/neoadjuvant setting.